IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) + Paclitaxel + Carboplatin + Olaparib + Niraparib
Phase 3Recruiting 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Epithelial Ovarian Cancer
Conditions
Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Trial Timeline
Jul 9, 2025 → Oct 31, 2032
NCT ID
NCT06915025About IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) + Paclitaxel + Carboplatin + Olaparib + Niraparib
IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) + Paclitaxel + Carboplatin + Olaparib + Niraparib is a phase 3 stage product being developed by IMUNON for Epithelial Ovarian Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06915025. Target conditions include Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer.
What happened to similar drugs?
4 of 12 similar drugs in Epithelial Ovarian Cancer were approved
Approved (4) Terminated (1) Active (8)
Hype Score Breakdown
Clinical
17
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06915025 | Phase 3 | Recruiting |
Competing Products
20 competing products in Epithelial Ovarian Cancer